114 related articles for article (PubMed ID: 6577781)
1. Influence of clofibrate, bile-sequestering agents and probucol on high-density lipoprotein levels.
Glueck C
Am J Cardiol; 1983 Aug; 52(4):28B-30B. PubMed ID: 6577781
[TBL] [Abstract][Full Text] [Related]
2. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
Kesäniemi YA; Grundy SM
JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
[TBL] [Abstract][Full Text] [Related]
3. Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
Tomikawa M; Nakayasu T; Tawara K; Abiko Y
Atherosclerosis; 1981 Oct; 40(2):101-13. PubMed ID: 6946776
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein fractions and receptors: a role for probucol?
Bilheimer DW
Am J Cardiol; 1986 Jun; 57(16):7H-15H. PubMed ID: 3637051
[TBL] [Abstract][Full Text] [Related]
5. Effects of probucol on lipoprotein protein kinetics.
Nestel PJ
Artery; 1982; 10(2):95-8. PubMed ID: 7092582
[TBL] [Abstract][Full Text] [Related]
6. Fibric acids: effects on lipids and lipoprotein metabolism.
Grundy SM; Vega GL
Am J Med; 1987 Nov; 83(5B):9-20. PubMed ID: 3318457
[TBL] [Abstract][Full Text] [Related]
7. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Kłosiewicz-Latoszek L; Szostak WB
Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
[TBL] [Abstract][Full Text] [Related]
8. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Vessby B; Lithell H; Gustafsson IB; Borberg J
Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
[TBL] [Abstract][Full Text] [Related]
9. Serum lipoprotein and apoprotein concentrations in 4-(4-chlorophenyl)-2-hydroxytetronic acid and clofibrate-treated cholesterol and cholic acid-fed rats.
Kamanna VS; Newman HA; Patel ST; Tehim AK; Witiak DT; Feller DR
Lipids; 1989 Jan; 24(1):25-32. PubMed ID: 2747427
[TBL] [Abstract][Full Text] [Related]
10. Mode of action and adverse effects of lipid lowering drugs.
Eghdamian B; Ghose K
Drugs Today (Barc); 1998 Nov; 34(11):943-56. PubMed ID: 14743263
[TBL] [Abstract][Full Text] [Related]
11. Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis.
Nestel PJ; Billington T
Atherosclerosis; 1981; 38(1-2):203-9. PubMed ID: 7470200
[TBL] [Abstract][Full Text] [Related]
12. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
[TBL] [Abstract][Full Text] [Related]
14. The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.
Atmeh RF; Stewart JM; Boag DE; Packard CJ; Lorimer AR; Shepherd J
J Lipid Res; 1983 May; 24(5):588-95. PubMed ID: 6875383
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of gemfibrozil on lipoprotein metabolism.
Saku K; Gartside PS; Hynd BA; Kashyap ML
J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
[TBL] [Abstract][Full Text] [Related]
16. Currently available hypolipidaemic drugs and future therapeutic developments.
Farmer JA; Gotto AM
Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):825-47. PubMed ID: 8593127
[TBL] [Abstract][Full Text] [Related]
17. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Nye ER; Sutherland WH; Temple Wa
N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
[TBL] [Abstract][Full Text] [Related]
18. Studies on hypoxic dyslipidaemia. Effect of lipid modulating drugs.
Mälkönen M; Muona M; Manninen V
Acta Med Scand Suppl; 1982; 668():130-5. PubMed ID: 6963088
[TBL] [Abstract][Full Text] [Related]
19. Medical management of hyperlipidemia and the role of probucol.
Davignon J
Am J Cardiol; 1986 Jun; 57(16):22H-28H. PubMed ID: 3460320
[TBL] [Abstract][Full Text] [Related]
20. Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.
Homma Y; Kobayashi T; Yamaguchi H; Sakane H; Ozawa H; Matsuda M; Mikami Y; Mikami Y; Nakamura H
Artery; 1993; 20(1):1-18. PubMed ID: 8447724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
